Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Price Controls in Action: Understanding the Rise of the 340B Program

This article was originally published in RPM Report

Executive Summary

The health care reform law dramatically expanded the number of entities eligible to purchase drugs via the federally administered 340B program, while simultaneously increasing the size of the mandatory discounts given to covered entities. Manufacturers are understandably frustrated. Rather than hope for elimination of the program, however, they may be better served working within the system to contain its impact.

You may also be interested in...

340B Drug Discount Program Hits A Turning Point, But In Which Direction?

Long-awaited “mega-guidance” sets boundaries on discount and makes big changes for HIV drugs – and could mean the beginning of the end of the scrutiny of the program. A legislative proposal floated in the context of the “21st Century Cures” bill might move things in a different direction.

340B Meets Part B: Payment Proposal Unites Big Pharma and Safety Net Providers

The annual hunt for “pay-fors” is on: Congress is looking for offsets to pay for the cost of reversing physician payment cuts under Medicare. One idea would be to allow Medicare Part B to capture the prices of the 340B discount program. Providers who use 340B hate the idea – and manufacturers do too.

Biopharma Sizes Up The Affordable Care Act: Buyer’s Remorse Or Winner’s Curse?

Three years into the ACA, the biopharma industry takes stock of its near-term wins and losses as the law’s critical expanded insurance coverage takes effect beginning in 2014. Pharma still isn’t sure whether the increase in covered lives from the exchanges will boost prescription sales enough to offset the rebates, taxes, and fees it agreed to pay out, or what kind of patients constitute this new market.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts